The Brookbush Institute continues to enhance education with new articles, new courses, a modern glossary, an AI Tutor, ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing ...

The dangers for infection aren’t only caused by microbes, but also by the molecular signals they release. To detect and neutralize these signals, may be the next era for infectious disease control.” — ...

T Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related ...

Healthcare professionals have to change their perspective from viewing data as an asset to viewing patients as stakeholders whose trust underpins the entire system.

Biobots, whose growing line of variants started with xenobots, are fascinating tiny self-powered living robots built ...

In the management of Crohn’s disease, a key objective — preserving the bowel by reducing the need for multiple resections — ...

NOTCH3-ECD is a specific IPAH biomarker, Cloud-Clone’s SEL147Hu ELISA Kit powers this breakthrough HUSTON, TX, UNITED STATES, March 17, 2026 /EINPresswire.com/ — A groundbreaking study published in ...

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people ...

Discover how Commonwealth Fusion Systems is turning commercial nuclear fusion into a reality. Read about their $1.8B race for unlimited clean energy!

The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other therapeutics represents one of the most consequential regulatory developments in ...